Author Archives: xencor

09.24.12 – 09.26.12

Posted on by xencor

SMi’s Biosimilars and Biobetters (David E. Szymkowski, Ph.D., presenting; London, UK)

Posted in EVENTS | Comments Off

Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration

Posted on by xencor

SEVENTH ANTIBODY DEVELOPED WITH XENCOR’S XmAb TECHNOLOGY MOVES INTO HUMAN TRIALS MONROVIA, Calif., April 19, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited. The payment was …

Posted in PRESS RELEASES | Comments Off

05.20.12 – 05.23.12

Posted on by xencor

4th DIA China Annual Meeting (Bassil Dahiyat, Ph.D., Speaker; Shanghai, China)

Posted in EVENTS | Comments Off

Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement

Posted on by xencor

MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.  The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of …

Posted in PRESS RELEASES | Comments Off

03.26.12 – 03.28.12

Posted on by xencor

24th Annual EuroMeeting, Drug Information Association (David Szymkowski, Ph.D., presenting; Copenhagen, Denmark)

Posted in EVENTS | Comments Off

03.25.12 – 03.30.12

Posted on by xencor

Gordon Research Conference – Antibody Biology & Engineering (John Desjarlais, Ph.D., presenting; Galveston, TX)

Posted in EVENTS | Comments Off

03.19.12 – 03.22.12

Posted on by xencor

IBC’s 3rd Biotherapeutics Analytical Summit (David Szymkowski, Ph.D., presenting; Baltimore, MD)

Posted in EVENTS | Comments Off

02.29.12 – 03.02.12

Posted on by xencor

IBC’s 28th International Antibody Development & Production (David Szymkowski, Ph.D., presenting; San Diego, CA)

Posted in EVENTS | Comments Off

02.29.12 – 03.02.12

Posted on by xencor

Biobetters & Biosimilars – Technologies & Development Strategies (Bassil Dahiyat, Ph.D., presenting; San Diego, CA)

Posted in EVENTS | Comments Off

Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies

Posted on by xencor

Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life MONROVIA, Calif., USA and INGELHEIM, Germany – February 21, 2012 – Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and …

Posted in PRESS RELEASES | Comments Off

01.30.12 – 01.31.12

Posted on by xencor

4th Immunotherapeutics and Immunomonitoring Conference (John Desjarlais, Ph.D., presenting; San Diego, CA)

Posted in EVENTS | Comments Off

01.30.12 – 01.31.12

Posted on by xencor

Allergy Drug Discovery and Development Conference (Bassil Dahiyat, Ph.D., presenting; San Diego, CA)

Posted in EVENTS | Comments Off

Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US (2012)

Posted on by xencor

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Jan 13. [Epub ahead of print]

Posted in PUBLICATIONS | Comments Off

Chu SY, Horton H, Pong E, Leung I, Chen H, Nguyen D-H, Bautista C, Muchhal US, Bernett M, Moore GL, Szymkowski DE, Desjarlais JR (2012)

Posted on by xencor

Reduction of Total IgE by Targeted Coengagement of IgE B cell Receptor and FcgRIIb with Fc-Engineered Antibody. J Allergy Clin Immunol, doi:10.1016/j.jaci.2011.11.029

Posted in PUBLICATIONS | Comments Off

Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE (2012)

Posted on by xencor

Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcgRIIb. Immunol Lett, in press.

Posted in PUBLICATIONS | Comments Off

01.11.12 – 01.12.12

Posted on by xencor

Antibodies for the 21st Century (John Desjarlais, Ph.D., presenting; San Diego, CA)

Posted in EVENTS | Comments Off

Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA (2011)

Posted on by xencor

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs. Nov 1;3(6). [Epub ahead of print].

Posted in PUBLICATIONS | Comments Off

12.04.11 – 12.08.11

Posted on by xencor

Antibody Engineering and Antibody Therapeutics (John Desjarlais, Ph.D., San Diego, CA)

Posted in EVENTS | Comments Off

Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response

Posted on by xencor

Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company’s therapeutic antibody for the treatment of autoimmune diseases.

Posted in PRESS RELEASES | Comments Off

11.04.11 – 11.09.11

Posted on by xencor

American College of Rheumatology Annual Scientific Meeting (Matthew Bernett, Ph.D., presenting; Chicago, IL)

Posted in EVENTS | Comments Off

JR Desjarlais and GA Lazar (2011)

Posted on by xencor

Modulation of antibody effector function. Experimental Cell Research 317(9)1278-1285

Posted in PUBLICATIONS | Comments Off

10.11.11 – 10.13.11

Posted on by xencor

PEGS Europe – Protein & Antibody Engineering Summit (John Desjarlais, Ph.D., presenting; Hannover, Germany)

Posted in EVENTS | Comments Off

08.01.11 – 08.03.11

Posted on by xencor

Drug Discovery & Diagnostic Development (John Desjarlais, Ph.D., presenting; San Francisco, CA)

Posted in EVENTS | Comments Off

06.27.11 – 06.30.11

Posted on by xencor

2011 BIO International Convention (Bassil I. Dahiyat, Ph.D.; Washington, D.C.)

Posted in EVENTS | Comments Off

09.03.11 – 09.06.11

Posted on by xencor

IMPULSE 2011: Immune-related Pathologies: Understanding Leukocyte Signaling and Emerging Therapies (David E. Szymkowski, Ph.D., presenting; Visegrád, Hungary)

Posted in EVENTS | Comments Off